MedTrace Logo

Candida in the Respiratory Tract Secretions of Critically Ill Patients and The Efficacy of Antifungal Treatment

NCT00934934 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2021-02-01

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to determine whether the effect of treating Candida spp. isolated in the respiratory tract secretions of patients with a clinical suspicion of ventilator associated pneumonia (VAP) on clinical outcomes will be feasible and supported by biomarker data obtained.

Conditions

  • Ventilator Associated Pneumonia
  • Respiratory Tract Infection

Interventions

OTHER

Normal Saline

Normal Saline

DRUG

anidulafungin

TBA

Sponsors & Collaborators

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • Queen's University

    collaborator OTHER

  • Pfizer

    collaborator INDUSTRY

  • Daren K. Heyland

    lead OTHER

Principal Investigators

  • Daren Heyland, MD · Clinical Evaluation Research Unit

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00934934 on ClinicalTrials.gov